ArticleBlood2005
The kinetics of clonal dominance in myeloproliferative disorders.
Article in Blood, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Article
- A mixed-effects stochastic model reveals clonal dominance in gene therapy safety studies.BMC bioinformatics · 2023Article
- Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.Experimental hematology · 2022Review
- Review
- Study of cohabitation and interconnection effects on normal and leukaemic stem cells dynamics in acute myeloid leukaemia.IET systems biology · 2018Article
- Visualizing hematopoiesis as a stochastic process.Blood advances · 2018Article
- Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments.PLoS computational biology · 2017Article
- Article
- Prognosis of Primary Myelofibrosis in the Genomic Era.Clinical lymphoma, myeloma & leukemia · 2016Review
- The landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection.Nucleic acids research · 2016Article
- Normal vs. Malignant hematopoiesis: the complexity of acute leukemia through systems biology.Frontiers in genetics · 2015Article
- Mathematical modeling of therapeutic strategies for myeloid malignancies.Pathology oncology research : POR · 2012Article
- Global dynamics of hematopoietic stem cells and differentiated cells in a chronic myeloid leukemia model.Journal of mathematical biology · 2011Article
- Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.Experimental hematology · 2011Article
- Review
- Somatic and germline genetics at the JAK2 locus.Nature genetics · 2009Article
- Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.The Journal of clinical investigation · 2008Article
- Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.Journal of molecular medicine (Berlin, Germany) · 2008Review
- Insertional mutagenesis and clonal dominance: biological and statistical considerations.Gene therapy · 2008Review
- New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia.Blood cells, molecules & diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
To study clonal evolution in myeloproliferative disorders, we used stochastic models of hematopoiesis for mouse and cat, species for which the in vivo kinetics of hematopoietic stem cells (HSCs) have been experimentally defined. We determined the consequence if 1 HSC became able to survive without the support of a microenvironmental niche while the rest of its behavior did not change. Neoplastic cells persisted and dominated hematopoiesis in 14% of mice and 17% of cats, requiring mean times of 2.5 +/- 0.5 and 7.0 +/- 1.2 years, respectively (n=1000 simulations/species). In both species, when the number of neoplastic HSCs exceeded 0.5% of all HSCs, clonal dominance was inevitable. Our results can explain the absence of clonal myeloproliferative disorders in mice (lifetime, 2 years), are consistent with clinical observations in cats, and provide insight into the progression of chronic myelogenous leukemia (CML) in humans. They also demonstrate that competition for microenvironmental support can lead to the suppression of normal hematopoiesis as neoplasia evolves. Toxic or immunologic suppression of normal HSCs is not required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.